Case report of preoperative radiotherapy followed by surgery in patient with giant primary retroperitoneal G1 liposarcoma
https://doi.org/10.18027/2224-5057-2022-12-3-43-48
Abstract
Despite the development of contemporary surgical management of retroperitoneal liposarcomas, local recurrence remains the major challenge in the treatment of these tumors. Currently, surgery is the main treatment option for liposarcoma. The international cancer community faces a global goal — the development of new combined treatment options for the treatment of retroperitoneal liposarcoma to reduce the postoperative recurrence rate and increase the overall survival. This article presents the world literature data on the treatment of retroperitoneal liposarcomas and demonstrates a case report describing treatment of a patient with this disease in the N. N. Blokhin NMRC of Oncology.
About the Authors
Yu. I. Bart
N. N. Blokhin National Research Center of Oncology
Russian Federation
Russian Federation
Yulia I. Bart, radiation therapist
Moscow
D. A. Glibichuk
Peoples’ Friendship University of Russia
Russian Federation
Russian Federation
Dmitry A. Glibichuk, post-graduate student, Department of Oncology
Moscow
R. Sh. Abdulaeva
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Rukiyat Sh. Abdulaeva, second-year resident, Department of Oncology and Radiotherapy
Moscow
I. G. Avdyukhin
N. N. Blokhin National Research Center of Oncology
Russian Federation
Russian Federation
Ivan G. Avdyukhin, first-year postgraduate student, Department of Abdominal Surgical Oncology No. 6
Moscow
А. Е. Kalinin
N. N. Blokhin National Research Center of Oncology
Russian Federation
Russian Federation
Alexey E. Kalinin, MD, PhD, Senior Researcher, Acting Head of the Department of Abdominal Surgical Oncology No. 6
Moscow
M. V. Chernykh
N. N. Blokhin National Research Center of Oncology; Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
Marina V. Chernykh, MD, PhD, Head of the Radiotherapy Department, Deputy Medical Director; Associate Professor of the Department of Oncology, Radiotherapy and Plastic Surgery
Moscow
References
1. Ishii, K., Yokoyama, Y., Nishida, Y., Koike, H., Yamada, S., Kodera, Y., Sassa, N., Gotoh, M., & Nagino, M. (2020). Characteristics of primary and repeated recurrent retroperitoneal liposarcoma : Outcomes after aggressive surgeries at a single institution. Japanese Journal of Clinical Oncology, 50 (12), 1412–1418.
2. Lewis JJ, Leung D, Woodruff JM, Brennan MF. Retroperitoneal Soft-Tissue Sarcoma Analysis of 500 Patients Treated and Followed at a Single Institution. Ann Surg. 1998.
3. Miao, C.-L., Zhang, L.-L., Tseng, W. W., Qiu, F.-B., Lu, W.-Q., Dai, Y.-G., Rao, X.-S., Li, W.-J., Zhang, G.-K., Chen, J., Liu, W.-Q., Chen, X.-B., Xiao, M.-M., Cha, L.-C., Wang, J.-Y., Ren, Y.-B., Yang, H.-Y., & Luo, C.-H. (2022). A better overall survival (OS) for total (ipsilateral) retroperitoneal lipectomy than standard complete resection in patients with retroperitoneal liposarcoma : a comparative multi-institutional study. Annals of Translational Medicine, 10 (14), 785–785.
4. Gronchi A, Miceli R, Allard MA, Callegaro D, le Péchoux C, Fiore M, et al. Personalizing the Approach to Retroperitoneal Soft Tissue Sarcoma : Histology-specific Patterns of Failure and Postrelapse Outcome after Primary Extended Resection. Ann Surg Oncol. Springer New York LLC ; 2015 ; 22 : 1447–54.
5. Gronchi A, Ferrari S, Quagliuolo V, Broto JM, Pousa AL, Grignani G, et al. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001) : an international, open-label, randomised, controlled, phase 3, multicentre trial. Lancet Oncol. Lancet Publishing Group ; 2017 ; 18 : 812–22.
6. Gronchi A, Palmerini E, Quagliuolo V, Javier Broto M, Lopez Pousa A, et al. Neoadjuvant Chemotherapy in HighRisk Soft Tissue Sarcomas : Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups [Internet]. J Clin Oncol. 2020. Available from: www.sarculator.com
7. Ballo MT, Zagars GK, Pollock RE, Benjamin RS, Feig BW, Cormier JN, et al. Retroperitoneal soft tissue sarcoma : An analysis of radiation and surgical treatment. Int J Radiat Oncol Biol Phys. 2007 ; 67 : 158–63.
8. Bishop AJ, Zagars GK, Torres KE, Hunt KK, Cormier JN, Feig BW, et al. Combined modality management of retroperitoneal sarcomas : A single-institution series of 121 patients. Int J Radiat Oncol Biol Phys. Elsevier Inc. ; 2015 ; 93 : 158–65.
9. Zlotecki RA, Katz TS, Morris CG, Scott Lind D, Hochwald SN. Adjuvant radiation therapy for resectable retroperitoneal soft tissue sarcoma : The University of Florida experience. American Journal of Clinical Oncology : Cancer Clinical Trials. 2005 ; 28 : 310–6.
10. DeLaney TF, Chen YL, Baldini EH, Wang D, Adams J, Hickey SB, et al. Phase 1 trial of preoperative image guided intensity modulated proton radiation therapy with simultaneously integrated boost to the high risk margin for retroperitoneal sarcomas. Adv Radiat Oncol. Elsevier Inc ; 2017 ; 2 : 85–93.
11. Pawlik TM, Pisters PWT, Mikula L, Feig BW, Hunt KK, Cormier JN, et al. Long-term results of two prospective trials of preoperative external beam radiotherapy for localized intermediate- or high-grade retroperitoneal soft tissue sarcoma. Ann Surg Oncol. 2006 ; 13 : 508–17.
12. Bonvalot S, Gronchi A, le Péchoux C, Swallow CJ, Strauss D, Meeus P, et al. Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092 : STRASS) : a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. Lancet Publishing Group ; 2020 ; 21 : 1366–77.
Review
For citations:
Bart Yu. ., Glibichuk D.A., Abdulaeva R.Sh., Avdyukhin I.G., Kalinin А.Е., Chernykh M.V. Case report of preoperative radiotherapy followed by surgery in patient with giant primary retroperitoneal G1 liposarcoma. Malignant tumours. 2022;12(3):43-48. (In Russ.) https://doi.org/10.18027/2224-5057-2022-12-3-43-48
Views:
397
Email this article 